Aeon Raises £8.2 Million to Transform Preventative Healthcare with AI-Powered Full-Body Screening

Aeon Raises £8.2 Million to Advance Preventative Healthcare

Swiss healthtech company Aeon has secured £8.2 million in a seed funding round to develop an advanced platform focused on early detection and prevention of diseases. The round was led by London-based venture capital firm Concentric, with contributions from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and Swiss super angel investor Daniel Gutenberg, known for supporting companies such as Airbnb, Facebook, and SumUp.

Unlike typical consumer health platforms that rely on limited data sources like wearables or basic tests, Aeon combines full-body MRI scans, advanced blood biomarkers, and genetic information into a comprehensive 60-minute health check. This integration enables early detection and risk prediction for over 500 diseases, all reviewed by board-certified physicians and discussed directly with radiologists.

A key differentiator is Aeon’s clinical-grade follow-ups, which have maintained a 0% false positive rate so far. This reduces overdiagnosis and unnecessary procedures, challenges common in preventative healthcare.

Innovative Use of AI in Healthcare

Aeon employs artificial intelligence in three main ways:

• Automated imaging analysis: AI detects and measures anomalies on MRI scans, enhancing speed and consistency in evaluations.
• Cross-validation: AI correlates MRI, blood, and genetic data to minimize false positives and improve clinical relevance.
• Predictive modeling: AI generates personalized risk profiles, forecasting the likelihood of over 500 health conditions to support targeted prevention.

Non-communicable diseases cause 41 million deaths annually, a figure expected to rise by 27% by 2030, according to the World Health Organization. Despite 80% of these deaths being preventable, fragmented data and slow healthcare systems limit effective prevention efforts.

Since its 2024 launch, Aeon has identified early-stage cancers, aneurysms, Alzheimer’s, and other critical conditions in seemingly healthy individuals. One notable case involved a 56-year-old man whose undiagnosed kidney cancer was detected through a single scan, enabling timely surgery.

Reimbursement and Growth Strategy

Aeon is the first platform offering full-body check-ups eligible for reimbursement by health insurers. It has partnered with major Swiss insurers, including KPT, allowing customers to recover up to 80% of the cost depending on their insurance plans. This approach improves affordability and accessibility for proactive healthcare.

The new funding will support Aeon’s expansion into Switzerland, Germany, and the UK, with plans for additional international markets. The company aims to open over 10 new locations soon to grow its clinical network. Funds will also accelerate partnerships with insurers and employers and enhance Aeon’s AI platform for earlier and more accurate diagnoses.

Experienced Leadership Team

Aeon’s leadership includes CEO Tim Seithe, who previously founded and sold Tillhub to Unzer (owned by KKR), and CPO Samuel Frey, with a decade of product leadership experience and recent work in diagnostics turnaround at Platomics. Scientific advisor Dr. Andreas Lemke, a leading MRI physicist and founder of AI brain imaging company Mediaire, supports the team.

Tim Seithe explained, “We’re shifting preventive care from reactive checks to proactive health management. Our approach addresses one of the biggest challenges in prevention: false positives. Every customer receives a clear risk profile and a medically grounded plan to monitor and reduce health risks over time.”

Alex Stroud, Principal at Concentric, added, “Validated by insurers, Aeon delivers a medically sound preventive health product. This blend of clinical rigor and commercial scale sets them apart.”